Biotechnology - Licensing, Gastro-intestinals


Popular Filters

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave


French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Phenex in up to $135 million research collaboration with Janssen


Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb


USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

Ferring Pharma gains rights for elobixibat from Albireo


Swiss drugmaker Ferring Pharmaceuticals has entered into a licensing agreement with Albireo AB, a Sweden-based…

AlbireoBiotechnologyelobixibatFerring PharmaceuticalsGastro-intestinalsLicensingPharmaceutical

Back to top